In the BioHarmony Drug Report Database
Risankizumab-rzaa
Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.
Trade Name
|
Skyrizi |
|---|---|
Common Name
|
risankizumab |
ChEMBL ID
|
CHEMBL3990029 |
Indication
|
psoriasis |
Drug Class
|
Monoclonal antibodies: humanized, interleukins as target |
Image (chem structure or protein)
